{"entity":{"id":"nct06101134","kind":"trial","name":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed","aka":[],"tldr":"A phase 2 trial of Nivolumab, Relatlimab + nivolumab in melanoma, run by Bristol-Myers Squibb, active and no longer recruiting.","summary":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations is a phase 2 interventional study registered as NCT06101134 by Bristol-Myers Squibb, with 100 participants enrolled, started 2023-11-06 and due to reach its primary completion in 2025-04-10. Interventions recorded: relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab, nivolumab+rHuPH20. Conditions listed: Melanoma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06101134","url":"https://clinicaltrials.gov/study/NCT06101134"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nivolumab","relatlimab-nivolumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06101134","phase":"2","setting":"A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for Nivolumab + Relatlimab Fixed-dose Combination Subcutaneous Versus Nivolumab + Relatlimab Fixed-dose Combination Intravenous and Nivolumab Subcutaneous Versus Nivolumab Intravenous in Participants With Melanoma","sponsor":"Bristol-Myers Squibb","started":"2023-11-06","startedType":"actual","yearReported":2026,"enrolled":100,"enrolledBasis":"registry","outcomes":[{"endpoint":"Percentage of Evaluable Participants That Prefer SC Route of Administration Using the Patient Experience and Preference Questionnaire (PEPQ) (Question 7) After Cycle 4 Day 1 Dose","primary":true,"unit":"%","arms":[{"name":"Cohort 1: Metastatic Melanoma","n":41,"value":78,"note":"95% CI 62.4 to 89.4; Figures from the ClinicalTrials.gov results section (first posted 2026-04-09), not from a publication"},{"name":"Cohort 2: Resected Melanoma","n":48,"value":70.8,"note":"95% CI 55.9 to 83.0"}],"source":"https://clinicaltrials.gov/study/NCT06101134?tab=results"}]},"route":"/trials/nct06101134/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}